Back to Search Start Over

Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment.

Authors :
Chen, Yuang
Chen, Chien-Yu
Huang, Haozhe
Luo, Zhangyi
Mu, Yiqing
Li, Shichen
Huang, Yixian
Li, Song
Source :
Journal of Controlled Release. Jun2024, Vol. 370, p479-489. 11p.
Publication Year :
2024

Abstract

Scramblase Xk-related protein 8 (Xkr8) regulates the externalization of phosphatidylserine (PS) during apoptosis and holds a pivotal role in fostering tumor immunosuppression. Targeting Xkr8 in conjunction with chemotherapy demonstrated a novel avenue for amplifying antitumor immune response and overcoming chemo-immune resistance. Here we further evaluated this strategy by using a clinically relevant orthotopic model and elucidated the mechanism through in-depth single-cell RNA sequencing (scRNA-seq). We found that Xkr8 knockdown exhibited the potential to lead to immunogenic cell death (ICD) by impeding the normal clearance of apoptotic cells. Co-delivery of Xkr8 small interference RNA (siRNA) and a prodrug conjugate of 5-fluorouracil (5-Fu) and oxoplatin (FuOXP) showed remarkable therapeutic efficacy in an orthotopic pancreatic tumor model with increased infiltration of proliferative NK cells and activated macrophages in the tumor microenvironment (TME). Single-cell trajectory analysis further unveiled that tumor infiltrating CD8+ T cells are differentiated favorably to cytotoxic over exhausted phenotype after combination treatment. Our study sheds new light on the impact of Xkr8 knockdown on TME and solidifies the rationale of combining Xkr8 knockdown with chemotherapy to treat various types of cancers. [Display omitted] [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01683659
Volume :
370
Database :
Academic Search Index
Journal :
Journal of Controlled Release
Publication Type :
Academic Journal
Accession number :
177750920
Full Text :
https://doi.org/10.1016/j.jconrel.2024.04.041